Sharing is caring!

If you’ve dealt with recurring SIBO, the GLP-1 conversation cannot stop at weight loss, nausea, and reduced appetite.

We also need to talk about gut motility.

Because one of the ways GLP-1 medications work is by changing how quickly food moves through the digestive system.

And for someone whose SIBO has been connected to slow motility, constipation, gastroparesis, diabetes, or an impaired migrating motor complex, that matters.

A lot.

GLP-1 Medications and SIBO: Can Ozempic, Wegovy, Mounjaro, or Zepbound Trigger Bacterial Overgrowth?

Click HERE to save this article for later.

So, can Ozempic, Wegovy, Mounjaro, or Zepbound cause SIBO?

Here is the honest answer:

GLP-1 medications have not been proven to directly cause SIBO.

But new research has identified an association between GLP-1 use and diagnosed small intestinal bacterial overgrowth.

There is also a biologically plausible explanation for that association: GLP-1 medications can slow gastric emptying, reduce small-intestinal motility, and interfere with the fasting motor patterns that normally help move bacteria and leftover material through the small intestine.

That does not mean everyone taking a GLP-1 will develop SIBO.

It does mean that people with existing motility problems deserve a more thoughtful conversation than, “Nausea and constipation are normal. Just push through.”

The short answer: do GLP-1 medications cause SIBO?

Here is what we currently know:

GLP-1 medications affect movement throughout the gastrointestinal tract. Delayed stomach emptying is their best-known digestive effect. Human studies also show reduced small-intestinal motility and suppression of the migrating motor complex. Two studies published in 2025 identified a possible relationship between GLP-1 use and SIBO or intestinal methanogen overgrowth. Neither study proves that GLP-1 medications directly cause overgrowth. We do not yet know which medication, dose, duration, or patient characteristics carry the greatest risk.

So no, I would not tell every person with SIBO that GLP-1 medications are automatically off-limits.

I also would not dismiss worsening bloating, constipation, abdominal pain, nausea, or food intolerance as an insignificant price of weight loss.

A medication can be beneficial and still require careful monitoring.

Both things can be true.

What are GLP-1 medications?

GLP-1 stands for glucagon-like peptide-1.

It is a hormone naturally released in the gut after eating. It helps coordinate blood sugar regulation, insulin secretion, appetite, fullness, and digestion.

GLP-1 receptor agonist medications imitate some of these actions. Common examples include:

• Ozempic: semaglutide, approved for adults with type 2 diabetes.
• Wegovy: semaglutide, approved for chronic weight management and certain cardiovascular-risk indications.
• Rybelsus: oral semaglutide used for type 2 diabetes.
• Mounjaro: tirzepatide, approved for type 2 diabetes.
• Zepbound: tirzepatide, approved for chronic weight management and obstructive sleep apnea in certain adults.

Tirzepatide is technically a dual GIP and GLP-1 receptor agonist, but it is usually included in the broader GLP-1 conversation.

Ozempic and Wegovy contain the same active ingredient but have different approved indications and dosing schedules. The same is true for Mounjaro and Zepbound.

These medications can provide meaningful benefits for people living with type 2 diabetes, obesity, cardiovascular risk, and other metabolic conditions.

This is not an anti-GLP-1 article. It is a SIBO-aware GLP-1 article.

And that distinction is important.

The new research on GLP-1 medications and SIBO

Until recently, most conversations about GLP-1 medications and digestive health focused on nausea, vomiting, constipation, diarrhea, and delayed stomach emptying.

We now have early research looking more directly at bacterial and methanogen overgrowth.

1] The large 2025 GLP-1 and SIBO study

A 2025 retrospective study examined electronic health records from people with type 2 diabetes. This was the Sun et al. analysis using the TriNetX global database, published in Diagnostics in September 2025, and it was the first large-scale study to flag this association.¹

Researchers compared patients prescribed GLP-1 or dual GLP-1/GIP medications with patients taking other second-line diabetes medications. After matching, each group included more than 216,000 patients.

At 12 months, the rate of diagnosed SIBO was:

0.177 cases per 1,000 person-years among GLP-1 or dual-agonist users, and 0.083 cases per 1,000 person-years among patients using comparison medications.

The relative hazard was approximately twice as high in the GLP-1 group.

But make note: the absolute number of documented cases was still extremely low. The difference was not statistically significant at 3 or 6 months, and the longer-term findings were less conclusive.

This study gives us a signal. It does not give us proof.

It was retrospective, depended on medical coding, grouped multiple medications together, and could not control for every possible cause of SIBO. Breath-testing methods also vary significantly between clinics, which creates another layer of uncertainty. The study only included people with type 2 diabetes, so we cannot automatically assume the findings apply equally to people using these medications solely for weight management. And diabetes itself can affect nerves and gut motility.

Still, this was the first large study to show a measurable association between GLP-1 therapy and subsequent SIBO diagnosis. That deserves attention.

2] The 2025 Mayo Clinic overgrowth study

A second 2025 study, from Mayo Clinic gastroenterology, reviewed 99 GLP-1 users who later underwent testing for intestinal overgrowth.² Among this highly selected group:

30.6% had a positive breath test. Positive breath tests were predominantly associated with intestinal methanogen overgrowth, or IMO. Many participants also had diabetes, which may independently contribute to slow motility and overgrowth risk.

Culture-based testing produced even higher positivity rates (76.2% at a threshold of ≥10³ CFU/mL), although those results depended heavily on which bacterial threshold the researchers used.

This study is interesting, particularly because methane overgrowth is closely connected with constipation and slow transit.

But it cannot tell us that 30% of all GLP-1 users will develop overgrowth. These were people who were already symptomatic or concerning enough to be tested. There was no untreated control group.

So again, this is a signal. Not a final answer.

How could a GLP-1 medication contribute to SIBO?

To understand this connection, you first need to understand motility.

Motility is more than how often you poop

Gut motility refers to the coordinated muscular contractions that move food, liquid, waste, and bacteria through the digestive tract.

Different sections of the gastrointestinal tract have different jobs. Your stomach must grind food and release it into the small intestine. And your small intestine must mix food with digestive secretions, absorb nutrients, and move its contents forward. Your colon must absorb water and eventually move stool out of the body.

Having 1 bowel movement every day does not automatically mean that every section of your digestive tract is moving properly. And being constipated does not tell us where the problem began.

GLP-1 medications delay gastric emptying

Delayed gastric emptying means food remains in the stomach longer before moving into the small intestine. That contributes to earlier fullness and reduced food intake.

It can also contribute to nausea, vomiting, burping, reflux, upper abdominal pressure, feeling full after a very small meal, and feeling as though food is sitting in the stomach.

Delayed gastric emptying is an expected part of GLP-1 physiology. It is not automatically gastroparesis. And it is not automatically SIBO.

But persistent, clinically significant slowing can create digestive problems for certain people.

GLP-1 medications may also slow the small intestine

The stomach gets most of the attention. But SIBO occurs in the small intestine.

Human studies have shown that GLP-1 signaling can reduce small-intestinal motility, slow intestinal flow and transit, and suppress antroduodenal and jejunal contractions. This gives researchers a plausible mechanism for the emerging SIBO association.

Slower transit means bacteria have more time to remain, multiply, and ferment carbohydrates inside the small intestine.

For a person with no other risk factors, that may never become clinically meaningful. For someone who already has impaired motility, it could be the additional factor that pushes the system in the wrong direction.

The migrating motor complex matters

The migrating motor complex, or MMC, is a pattern of muscular contractions that occurs primarily during fasting periods. Think of it as the small intestine’s housekeeping cycle. It helps sweep leftover food particles, secretions, and excess bacteria through the small intestine between meals.

Impaired MMC activity is one recognized contributor to recurrent SIBO. Research has shown that GLP-1 can suppress this fasting motor activity.

For me personally, slow motility was one of the biggest reasons my SIBO kept returning.

I could kill bacteria and alter my diet. I could take every supplement. But if I did not address why material was sitting too long in my small intestine, I was only addressing one piece of the problem.

And for you, motility might also be one of the culprits.

Read also: Supplements to Increase Gut Motility.

Is this really SIBO, or is it a GLP-1 side effect?

This is where things get confusing. Many GLP-1 side effects overlap with the symptoms of SIBO, IMO, constipation, and gastroparesis.

Common GLP-1 digestive effects

These often begin or worsen after starting the medication or increasing the dose: nausea, early fullness, reduced appetite, burping, reflux, constipation, diarrhea, abdominal discomfort, and occasional vomiting.

These symptoms may improve as the body adjusts, although not always.

Possible SIBO symptoms

SIBO may include increasing bloating as the day progresses, excessive gas, abdominal discomfort, diarrhea, loose or greasy stool, mixed constipation and diarrhea, new food intolerances, unexplained nutrient deficiencies, and weight loss that exceeds what would be expected from reduced intake.

SIBO symptoms are not specific enough to diagnose SIBO by themselves.

Possible IMO symptoms

IMO stands for intestinal methanogen overgrowth. It is not technically bacterial overgrowth, because methanogens belong to a different group of microorganisms called archaea.

IMO is commonly associated with constipation, slow transit, hard stool, incomplete bowel movements, bloating, and abdominal pressure.

Methane may be detected in either the small or large intestine, which is why IMO is not simply called “methane SIBO.”

Possible gastroparesis symptoms

Gastroparesis is delayed stomach emptying without a physical blockage. Symptoms may include feeling full very quickly, prolonged fullness after eating, upper abdominal pain or pressure, nausea, vomiting undigested food, difficulty eating enough food, and unstable blood sugar.

Gastroparesis and SIBO can coexist. But delayed stomach emptying does not automatically prove that bacterial overgrowth is present.

The symptoms overlap, and one condition can be mistaken for another.

A simple symptom comparison

This table is not a diagnostic tool. It is meant to help you identify patterns worth discussing with your healthcare provider.

Who may need extra caution?

There is not yet a validated checklist identifying exactly who will develop SIBO while using a GLP-1 medication. But I would have a more detailed motility conversation with a provider if I had a history of:

Recurrent SIBO, intestinal methanogen overgrowth, chronic constipation, known gastroparesis, diabetes-related autonomic neuropathy, previous abdominal or intestinal surgery, connective tissue disorders that affect motility, significant untreated hypothyroidism, regular opioid use, or medications that substantially slow gastrointestinal movement.

None of these automatically means you cannot use a GLP-1. They mean that the decision deserves more context.

The medication is only one part of the equation. Your existing motility, medication list, medical history, dose, rate of dose escalation, hydration, food intake, and symptom pattern all matter.

What about the gut microbiome?

You may have heard that GLP-1 medications “destroy the microbiome” or that they “improve the microbiome.” Neither statement is currently supported as a universal truth.

A 2025 systematic review evaluated 38 studies investigating GLP-1 medications and the gut microbiome. Only 9 were human studies. The rest used animal models. The human findings were inconsistent, and the studies differed in medication, duration, diet, disease status, sequencing methods, and other factors.

Also make note: most microbiome studies analyze stool. SIBO occurs in the small intestine. A stool sample cannot directly tell us what is happening in the upper small intestine.

So while GLP-1 medications may alter the gut microbial environment, we do not yet have enough evidence to label those changes universally good or bad.

Should everyone taking a GLP-1 be tested for SIBO?

No. The large 2025 cohort researchers did not recommend testing every GLP-1 user. They recommended symptom-driven evaluation.

That makes sense. Testing every person would likely produce unnecessary expense, confusing results, and overtreatment.

But testing may be reasonable when someone develops persistent or worsening symptoms such as significant bloating, severe constipation, new food intolerance, ongoing diarrhea, excessive gas, abdominal pain, unexplained nutrient deficiencies, or symptoms that continue despite adjusting the GLP-1 plan with the prescriber.

Before assuming SIBO, a clinician may also evaluate for constipation, gastroparesis, gallbladder disease, pancreatic disease, medication intolerance, obstruction, celiac disease, thyroid dysfunction, or another digestive condition.

Because bloating does not always equal SIBO. And nausea does not always equal gastroparesis.

How is SIBO tested?

Hydrogen and methane breath testing is the most common noninvasive option. During the test, you consume a measured amount of glucose or lactulose. Breath samples are then collected over a set period to measure gases produced by microorganisms.

A complete test should measure hydrogen, methane, and ideally both gases throughout the full collection period. Hydrogen sulfide testing is also becoming available, although access and interpretation remain more limited.

Glucose and lactulose each have benefits and limitations. Testing methods, patient preparation instructions, collection times, and report quality continue to vary between laboratories. A 2025 review of real-world breath-testing reports found substantial inconsistency in how testing was performed and interpreted.

This is why the test should be interpreted alongside symptoms, bowel patterns, medical history, medication use, previous treatment response, and other possible diagnoses.

Checkout my Complete Guide to SIBO Testing for more information.

Should you stop a GLP-1 before a SIBO breath test?

There is not one universally accepted GLP-1 washout rule used by every breath-testing laboratory. And because these medications can affect gastrointestinal transit, they could theoretically influence how quickly the test substrate moves through the digestive tract. That is an inference based on their motility effects, not a well-established breath-testing protocol.

Do not stop Ozempic, Wegovy, Mounjaro, Zepbound, or another prescribed medication on your own. Instead:

1. Tell the ordering clinician which GLP-1 medication you take.
2. Include the dose and the date of your most recent injection.
3. Ask the testing laboratory for its current medication-preparation instructions.
4. Let your prescriber decide whether holding the medication is medically appropriate.

This is especially important for someone using the medication for diabetes management.

A SIBO-aware plan for using a GLP-1 medication

You do not need to choose between fear and ignoring your symptoms. There is a middle ground.

1] Tell your prescriber about your SIBO history

Do this before beginning treatment when possible. Include previous SIBO or IMO test results, your dominant symptoms, history of gastroparesis or constipation, previous motility treatments, abdominal surgeries, and medications and supplements that affect bowel function.

Your history provides context that a weight, glucose, or A1c measurement cannot.

2] Establish your baseline

Before the first dose, record your average number of bowel movements per week, stool consistency, usual degree of bloating, nausea or reflux, how quickly you become full, typical food intake, and any existing abdominal pain.

Without a baseline, it can be difficult to tell whether a symptom is genuinely new.

3] Pay attention after dose changes

Digestive symptoms commonly become more noticeable during dose escalation. Do not increase the dose faster than prescribed. And do not assume you must reach the highest dose for the medication to be worthwhile.

Persistent vomiting, worsening constipation, inability to eat enough, severe bloating, or escalating pain should be discussed with the prescriber rather than treated as a willpower problem. Official prescribing information for semaglutide and tirzepatide warns that severe gastrointestinal reactions can occur and states that these medications are not recommended for patients with severe gastroparesis.³⁴

4] Address constipation early

Constipation is not simply an inconvenience for a SIBO-prone person. It is a clue that transit may be slowing. Discuss a constipation plan with your healthcare provider before the situation becomes severe.

That plan may involve changes to hydration, electrolyte intake, food volume, fiber type and amount, physical movement, magnesium or another clinician-approved option, and prescription motility support.

More fiber is not automatically the answer for every bloated or severely constipated person. Adding large amounts of fermentable fiber to an already backed-up digestive tract may make symptoms worse.

5] Give the migrating motor complex a chance to work

The MMC is primarily active during fasting periods rather than while food is continuously entering the digestive tract. For some people, constant grazing may reduce the time available for these fasting contractions.

But this is not permission to under-eat. GLP-1 medications already reduce appetite. If nausea, early fullness, or weight loss is making it difficult to meet basic nutritional needs, adequate intake becomes the priority.

The goal is not extreme fasting. The goal is a meal pattern that supports your body, medication tolerance, blood sugar, nutritional status, and motility.

6] Protect nutrition and hydration

Rapidly reduced food intake can affect protein intake, iron, B vitamins, zinc, electrolytes, hydration, muscle mass, and hair growth [which I already talked about in Ozempic Side Effects Hair Loss, GI Motility].

This does not mean the medication directly depletes every nutrient. It means that eating substantially less food, vomiting, diarrhea, or avoiding entire food groups can make nutritional adequacy more difficult.

A registered dietitian familiar with both GLP-1 therapy and gastrointestinal disorders can be extremely helpful here.

7] Investigate persistent symptoms instead of guessing

If significant symptoms continue, do not immediately assume “the medication is working,” “this is detox,” “it must be SIBO,” or “I just need another supplement.”

Find the reason. Then address the reason.

That may mean evaluating dose tolerance, constipation, gastroparesis, SIBO, IMO, medication interactions, gallbladder disease, or another condition.

GLP-1 medications and gastroparesis

Gastroparesis has become one of the most discussed GLP-1 complications. But we need to use the term correctly.

Gastroparesis is not simply feeling full after a meal. It is objectively delayed stomach emptying without a mechanical obstruction, usually confirmed through appropriate testing.

A 2025 observational analysis of people with obesity but without diabetes found a higher rate of diagnosed gastroparesis among GLP-1 users than among comparison groups. However, observational studies cannot eliminate every confounding factor or prove that the medication directly caused each case.

The FDA-approved prescribing information now clearly acknowledges severe gastrointestinal reactions and advises against using these medications in patients with severe gastroparesis.³⁴

That is different from claiming every person with temporary nausea has permanent stomach paralysis.

Words matter. Accuracy matters. Fear does not help anyone make a better decision.

That being said, here is a direct testimonial from someone who uses the Break Down product because of a GLP-1 issue.

What about intestinal obstruction or ileus?

Reports of intestinal obstruction and ileus have raised concern. But the research is mixed.

Some pharmacovigilance reports and observational analyses have identified possible signals. Other large studies have not found a significant increase in intestinal obstruction compared with other diabetes treatments, including a 2025 multinational cohort of people with type 2 diabetes. A separate Danish study did not find increased obstruction or ileus among GLP-1 users with inflammatory bowel disease.

This does not mean obstruction cannot occur. It means current evidence does not support claiming that GLP-1 medications commonly cause intestinal blockage.

Seek urgent medical care for severe or rapidly worsening abdominal pain, major abdominal swelling, repeated vomiting, inability to keep fluids down, inability to pass stool or gas, fainting or signs of significant dehydration, fever with severe abdominal symptoms, yellowing of the skin or eyes, or black or bloody stool.

Do not try to treat these symptoms at home with more fiber, laxatives, digestive enzymes, or SIBO supplements.

Other GLP-1 side effects to know

1] Common digestive side effects

The most common adverse effects include nausea, vomiting, diarrhea, constipation, and abdominal pain.

In Wegovy weight-management trials, gastrointestinal reactions were reported by 73% of treated adults compared with 47% receiving placebo. Most nausea, vomiting, and diarrhea occurred during dose escalation.³

These symptoms were not all severe. But “common” does not mean they should be ignored when they are persistent or significantly interfere with eating, hydration, bowel movements, or daily life.

2] Gallbladder problems

Weight loss and GLP-1 therapy have both been associated with gallstones and gallbladder inflammation. Symptoms such as upper-right abdominal pain, fever, jaundice, or pain after meals deserve medical evaluation.

3] Pancreatitis

Pancreatitis is an uncommon but serious concern listed in prescribing information. Persistent severe abdominal pain, particularly pain that travels toward the back or occurs with vomiting, requires prompt medical attention.

4] Hair loss

Hair loss has also been reported during GLP-1-assisted weight loss. The Zepbound prescribing information describes hair loss as associated with weight reduction and reports that it occurred more frequently among women in clinical trials.⁴

In many cases, hair shedding may be indirectly connected with rapid weight loss, reduced calorie intake, inadequate protein, iron or zinc deficiency, physical stress, hormonal changes, or telogen effluvium.

Hair loss should not automatically be blamed on the drug molecule itself. It is also not something to ignore. Nutritional status, thyroid function, weight-loss speed, protein intake, iron status, and other causes may need to be reviewed.

Will SIBO go away after stopping a GLP-1?

We do not have enough research to promise that stopping a GLP-1 will resolve SIBO.

If the medication contributed to slower transit, changing or discontinuing it under medical supervision might help remove one motility stressor. But SIBO is rarely explained by one isolated factor.

A person may still have diabetes-related neuropathy, chronic constipation, low thyroid function, previous abdominal surgery, adhesions, structural abnormalities, impaired MMC activity, another medication affecting motility, or an underlying digestive disorder.

Stopping the medication also does not treat an established overgrowth by itself. And stopping suddenly may carry real consequences for blood sugar, appetite, cardiovascular risk, or weight regain.

This decision belongs between you and the prescribing clinician.

Can you take a prokinetic with a GLP-1?

A prokinetic is a medication or supplement intended to support gastrointestinal movement. Some people with recurring SIBO use a prokinetic after antimicrobial treatment to support the migrating motor complex.

But combining a GLP-1 medication with a prescription or supplemental motility agent is not something to improvise.

Different products affect different parts of the digestive tract. They may also interact with heart rhythm, blood pressure, blood sugar, other medications, diarrhea or constipation, and existing motility disorders.

Bring your full medication and supplement list to the clinician managing your GLP-1 therapy.

Questions to ask before starting or continuing a GLP-1

Bring these questions to your appointment:

1. Could my history of SIBO, IMO, constipation, or gastroparesis change how we use this medication?
2. Which symptoms should I expect during dose escalation?
3. Which symptoms mean I should contact you immediately?
4. What is our plan if my bowel movements slow significantly?
5. Do I need a lower dose or slower titration schedule?
6. How will we monitor hydration and nutritional intake?
7. At what point would you evaluate for gastroparesis or SIBO?
8. Could another medication I take be adding to the motility problem?
9. Who should manage my digestive symptoms: you, my gastroenterologist, or both?
10. What would make the benefits no longer outweigh the digestive side effects?

Write the answers down. Structure calms chaos. And you should not have to guess your way through a medication that affects nearly every part of your digestive system.

In the gut-healing journal, there is a specific place to write down questions and answers at your doctor’s appointment.

Final thoughts on GLP-1 medications and SIBO

I am not going to tell you that GLP-1 medications are good. I am also not going to tell you they are bad. That is far too simplistic.

For some people, these medications provide meaningful improvements in blood sugar, metabolic health, mobility, cardiovascular risk, and quality of life. For others, the digestive side effects may become too significant. And for someone with a history of recurring SIBO, the motility piece deserves extra attention.

The current research does not prove that GLP-1 medications directly cause SIBO.

But it gives us enough information to stop dismissing the possibility that slowed gastrointestinal transit could contribute to overgrowth in susceptible people.

Despite the fact that there is research to prove both, the research I’m most interested in are the lengthy conversations and emails I’ve been getting from people who have been on these medications.

These people are not part of any research. They have not shared with their doctors. But they are telling me things like:

• My digestion has never been the same.
• I can’t go to the bathroom without a laxative.
• My stomach constantly hurts, and I don’t know what to do.

Proof is in the pudding.

The useful question isn’t only whether this medication helps you lose weight. It’s whether it’s improving your health without pushing your already-vulnerable motility in the wrong direction.

Track your symptoms. Know your baseline. Ask better questions. And work with a provider who is willing to look at the whole picture.

If you liked this article, you might also enjoy:

1. Personalized Weight Loss Plan for My Body
2. Food Sensitivity Test for Weight Loss
3. Weight Loss Through Optimal Gut Health

Xox,

SKH

Medical note: This article is for educational purposes and is not a substitute for diagnosis, treatment, or individualized medical advice. Do not begin, change, or stop a prescription medication without consulting the prescribing healthcare professional.

1. https://pmc.ncbi.nlm.nih.gov/articles/PMC12427755/ ↩︎
2. https://journals.sagepub.com/doi/10.1177/26345161251353437 ↩︎
3. https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/215256s024lbl.pdf ↩︎
4. https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/217806Orig1s020lbl.pdf ↩︎